• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Sight Sciences Inc.

    6/5/25 4:46:57 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care
    Get the next $SGHT alert in real time by email
    8-K
    false 0001531177 0001531177 2025-06-05 2025-06-05
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 5, 2025

     

     

    Sight Sciences, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-40587   80-0625749
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    4040 Campbell Avenue

    Suite 100

     
    Menlo Park, California   94025
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: 877 266-1144

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     


    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $0.001 par value per share   SGHT   Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02.

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    As previously disclosed, on April 21, 2025, the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Gerhard F. Burbach to the Board. Mr. Burbach has been appointed to serve on the Audit Committee.

     

    Item 5.07.

    Submission of Matters to a Vote of Security Holders.

    On June 5, 2025, the Company held its annual meeting of stockholders (the “Annual Meeting”). There were 51,695,688 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), outstanding and entitled to vote at the Annual Meeting at the close of business on April 9, 2025, the record date for the Annual Meeting (the “Record Date”). At the Annual Meeting, 38,814,229 shares of Common Stock were present virtually or represented by proxy, representing approximately 75.1% of the shares of Common Stock outstanding on the Record Date.

    Set forth below are the voting results for the proposals considered and voted upon at the Annual Meeting, each of which are described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 23, 2025.

    Proposal 1 – Election of three Class I directors to serve as directors of the Company until the annual meeting of stockholders to be held in 2028, or until each such director’s respective successor has been duly elected and qualified, or until each such director’s earlier death, resignation or removal.

     

    Name of Director    For    Withheld    Broker Non-Votes

    Paul Badawi

       24,675,076    1,039,257    13,099,896

    Brenda Becker

       20,923,888    4,790,445    13,099,896

    Erica Rogers

       23,914,492    1,799,841    13,099,896

    Proposal 2 – Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    38,080,605   26,937   706,687   —

    Based on the foregoing votes, Paul Badawi, Brenda Becker and Erica Rogers were elected as Class I directors, and the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was duly ratified.

    No other matters were presented for consideration or stockholder action at the Annual Meeting.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          Sight Sciences, Inc.
    Date: June 5, 2025     By:  

    /s/ Alison Bauerlein

          Chief Financial Officer
    Get the next $SGHT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGHT

    DatePrice TargetRatingAnalyst
    12/6/2024$5.50Buy
    UBS
    11/4/2024$10.00 → $5.00Buy → Hold
    Lake Street
    8/21/2024$10.00Buy
    Lake Street
    9/12/2023$10.00 → $4.50Neutral → Underperform
    BofA Securities
    9/12/2023$15.00 → $5.50Overweight → Neutral
    Piper Sandler
    9/12/2023Outperform → Mkt Perform
    William Blair
    8/24/2023$12.00 → $8.40Overweight → Equal-Weight
    Morgan Stanley
    7/10/2023$15.00 → $9.00Buy → Neutral
    Citigroup
    More analyst ratings